Opko Health, Inc. - Jul 24, 2024 Form 4 Insider Report for GeneDx Holdings Corp. (WGS)

Role: 10%+ Owner
Signature: Steven D. Rubin, Exec. VP - Administration
Stock symbol: WGS
Transactions as of: Jul 24, 2024
Transactions value $: -$4,560,363
Form type: 4
Date filed: 7/26/2024, 07:49 PM
Previous filing: Jul 23, 2024
Next filing: Jul 31, 2024

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	WGS	Class A Common Stock	Sale	-$2.53M	-75K	-2.3%	$33.72	3.18M	Jul 24, 2024	Direct	F1
transaction	WGS	Class A Common Stock	Sale	-$2.03M	-60K	-1.88%	$33.85	3.12M	Jul 26, 2024	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.33 to $34.33, inclusive. The reporting person undertakes to provide to GeneDx Holding Corp. (the "Company"), any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in footnote (1) to this Form 4.
F2	The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.50 to $34.66, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in footnote (2) to this Form 4.

Content

The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.33 to $34.33, inclusive. The reporting person undertakes to provide to GeneDx Holding Corp. (the "Company"), any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in footnote (1) to this Form 4.

The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.50 to $34.66, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in footnote (2) to this Form 4.